“EFFECT OF COENZYME Q10 SUPPLEMENTATION ON OVARIAN RESPONSE AND IVF OUTCOMES IN WOMEN WITH POOR OVARIAN RESERVE: A RANDOMIZED CONTROLLED TRIAL IN A IVF CENTER”
Main Article Content
Keywords
Coenzyme Q10; Diminished ovarian reserve; In vitro fertilization; Oocyte quality; Antioxidants; Mitochondrial function.
Abstract
Diminished ovarian reserve (DOR) is a significant contributor to infertility and low response to in vitro fertilization (IVF) stimulation that may result in inadequate pregnancy outcomes. Coenzyme Q10 (CoQ10) is an antioxidant and cofactor in the mitochondrion that has demonstrated the potential to enhance the quality and energy metabolism of the oocytes.
Objective: To identify the effect of Coenzyme Q10 supplementation on the ovarian response and the IVF outcome of women with poor ovarian reserve.
Methods: The study was a randomized controlled trial, which was carried out at the Khaula Hospital, IVF Center, Muscat. April 2024 June 2024. Eighty women with low ovarian reserve were randomly placed under CoQ10 (200mg/day) and placebo for eight weeks before IVF stimulation. All the subjects had undergone a standard gonadotropin-releasing hormone (GnRH) antagonist therapy.
Results: CoQ10 supplementation significantly improved ovarian response parameters, including mean oocytes retrieved (6.2 ± 1.8 vs. 3.9 ± 1.5; p<0.001), mature oocytes (4.8 ± 1.6 vs. 2.9 ± 1.3; p<0.001), and fertilization rate (68.4% vs. 52.3%; p<0.001). The proportion of Grade I embryos and clinical pregnancy rates were also higher in the CoQ10 group (65% and 35%, respectively) compared with controls (42% and 17.5%; p<0.05).
Conclusion: Coenzyme Q10 supplementation enhances ovarian function, oocyte quality, and IVF outcomes in women with poor ovarian reserve. It represents a promising, non-invasive adjunct to standard ovarian stimulation protocols in assisted reproduction.
References
2. Dawoud, M., Abd Al Waheed, A. T., Allah, S. H., Abd Al Kader Hemila, F., Abd El Mohsen, A. E., & Ogila, A. I. (2024). Does adding coenzyme Q10 to dehydroepiandrosterone sulphate positively impact fertility outcomes in young, poor responder infertile women undergoing antagonist protocol for IVF/ICSI cycles? South African Journal of Obstetrics and Gynaecology, 30(1), 27–30.
3. Abu-Zaid, A., Alghamdi, G. A., Alharbi, A. S., Baradwan, S., Saleh, S. A., Adly, H. M., Alzayed, M. M., Abuzaid, M., Sindi, R., Alsabban, M., & Alomar, O. (2024). Effect of L-carnitine supplementation on fertility outcomes among patients with polycystic ovary syndrome: A systematic review and dose-response meta-analysis of randomized clinical trials. Korean Journal of Obstetrics & Gynecology.
4. Bhide, P. (n.d.). The role of ovarian reserve markers in fertility and fertility treatment.
5. Han, Q. S., Wu, Z. J., Zhou, Y., Liang, J. N., Jin, Q. M., Song, J. Y., & Sun, Z. G. (2023). Effectiveness of oestrogen pretreatment in patients with expected poor ovarian response (POSEIDON groups 3 and 4) undergoing GnRH antagonist protocol: Study protocol for a randomised controlled trial. BMJ Open, 13(8), e069840.
6. Tang, H., Wang, J. X., Zheng, S. Z., Jia, Y. F., Yu, X., Zhao, N. N., Yang, Y. H., Lin, L. P., Li, S. Y., & Zhao, H. (2024). Electro-acupuncture for diminished ovarian reserve: Protocol for a randomized, placebo-controlled trial. Journal of Multidisciplinary Healthcare, 18, 4341–4352.
7. Potiris, A., Stavros, S., Alyfanti, E., Machairiotis, N., Drakaki, E., Zikopoulos, A., Moustakli, E., Skentou, C., Drakakis, P., & Domali, E. (2024). Metabolomics-driven insights into biomarkers for poor ovarian response: A narrative review. Biomedicines, 13(1), 214.
8. Tülek, F., & Kahraman, A. (2021). Effects of growth hormone co-treatment on in vitro fertilization outcomes in women with expected normal ovarian response. Turkish Journal of Obstetrics and Gynecology, 18(4), 285–291.
9. Han, Q. S., Zhou, Y., Chen, W., Song, J. Y., & Sun, Z. G. (2023). The role of Erzhi Tiangui formula in expected poor ovarian responders undergoing in vitro fertilization-embryo transfer: A multicenter, randomized, double-blind, placebo-controlled trial. Medicine, 102(27), e34088.
10. Erdoğan, K., Şanlıer, N., Utlu, E., Güvey, H., Kahyaoğlu, İ., Neşelioğlu, S., Erel, Ö., Akar, S., & Engin-Üstün, Y. (2023). Serum and follicular fluid thiol/disulfide homeostasis in diminished ovarian reserve patients undergoing in vitro fertilization/intracytoplasmic sperm injection treatment. Cureus, 15(2), e35026.
11. Ziaei, R., Ghasemi-Tehrani, H., Movahedi, M., Kalatehjari, M., Vajdi, M., Mokari-Yamchi, A., Elyasi, M., & Ghavami, A. (2023). The association between Diet Quality Index–International score and risk of diminished ovarian reserve: A case–control study. Frontiers in Nutrition, 10, 1277311.
12. Han, P., Xu, H., Yuan, Y., Wen, Z., Yang, J., Han, L., & Zhang, D. (2024). The role of growth hormone in assisted reproductive technology for patients with diminished ovarian reserve: From signaling pathways to clinical applications. Frontiers in Endocrinology, 16, 1551126.
13. Chen, H., Teng, X. M., Sun, Z. L., Yao, D., Wang, Z., & Chen, Z. Q. (2022). Comparison of the cumulative live birth rates after one in vitro fertilization cycle in women using gonadotropin-releasing hormone antagonist protocol vs. progestin-primed ovarian stimulation: A propensity score–matched study. Fertility and Sterility, 118(4), 701–712.
14. Chang, C. L. (2023). Facilitation of ovarian response by mechanical force—Latest insight on fertility improvement in women with poor ovarian response or primary ovarian insufficiency. International Journal of Molecular Sciences, 24(19), 14751.
15. Chen, D., Shen, X., Wang, L., & Kuang, Y. (2022). Cumulative live birth rates for low-prognosis women over five years or nine frozen-thawed embryo transfer cycles. BMC Pregnancy and Childbirth, 22(1), 233.
16. Man, L., Lustgarten Guahmich, N., Vyas, N., Tsai, S., Arazi, L., Lilienthal, D., Schattman, G., Rosenwaks, Z., & James, D. (2022). Ovarian reserve disorders—Can we prevent them? A review. International Journal of Molecular Sciences, 23(23), 15426.
17. Liu, Y., Lin, J., Shen, X., Zhu, Q., & Kuang, Y. (2023). Letrozole co-treatment improves the follicular output rate in high-body-mass-index women with polycystic ovary syndrome undergoing IVF treatment. Frontiers in Endocrinology, 14, 1072170.
18. Zhang, Y., Li, H., Zhu, S., Jiang, S., Zhao, W., Wang, X., Tian, L., Zhao, G., He, N., Diao, H., & Cao, H. (2023). The comparison between fixed versus degressive doses of medroxyprogesterone acetate combined with letrozole in patients of progestin-primed ovarian stimulation protocol: A propensity score-matched study. Frontiers in Endocrinology, 14, 1295787.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Dr Samiha Samad
Consultant, Department Obstetrics & Gynaecology, FCPS, MCPS Obstetrics & Gynecology, Sohar Hospital, Sohar/Oman
Dr Naseema Anjum
Consultant, Department Obstetrics & Gynaecology, FCPS, Obstetrics & Gynecology, Bugshan Hospital , Jeddah Saudi Arabia ( KSA)
Dr Nazish Zareen
Consultant, Department Obstetrics & Gynaecology, FCPS Obstetrics & Gynecology, Omar Hospital and Cardiac Centre Johar Town Lahore, Pakistan.
Dr Sabira Khuda Bakhsh
Medical Officer, Department of Obstetrics and Gynaecology, Membership in Obstetrics & Gynecology, Sohar Hospital, Sohar/Oman
Dr Shazia Ali
Consultant, Department Obstetrics & Gynaecology, FCPS, Obstetrics & Gynecology, Indus Hospital & Health Network (IHHN) Gwadar Pakistan
Dr Rameesha Sarfraz
Medical student, MD Program 4th semester Tiblisi State Medical University Gorgia
